My Blue Dots

MILAN, Italy & MORRISTOWN, New Jersey & SEOUL, Republic of Korea–(BUSINESS WIRE)—- $NWRN #schizophrenia–Newron and Myung In Pharm, South Korea’s leading specialist CNS pharma company, announce license agreement for evenamide in South Korea.

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT. A live webcast of the presentat

BASEL, Switzerland–(BUSINESS WIRE)–Demonstrated Robust Dose-Dependent Target Engagement, Preliminary Evidence of Improved Organ Function and a Favorable Safety Profile

ESSEX, Conn.–(BUSINESS WIRE)– #BLT1–Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis, today announced that the company has secured an additional $8.975 million in program-related investment funding in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust (“Helmsley”), bringing Helmsley’s t

SAN MATEO, Calif.–(BUSINESS WIRE)–Mendaera Inc., a healthcare technology company creating a first-of-its-kind handheld robotic platform to revolutionize the delivery of prevalent interventional procedures, today announced the appointment of Eric Davidson as its first Chief Commercial Officer (CCO). Davidson will lead commercialization efforts as the company prepares for market entry with its novel robotic technologies. Davidson joins Mendaera with more than two decades of leadership in medica

MELVILLE, N.Y.–(BUSINESS WIRE)–Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers throughout California that the Henry Schein Customer Emergency Support Hotline is open for dental and medical professionals who may experience operational, logistical, or financial issues as a result of damage caused by the ongoing fires. The toll-free number for all Henry Schein customers is 800-999-9729. The hotline is open 24/7, with real-time assistance available from Team Schein Members from 8 a.m. to

SEATTLE–(BUSINESS WIRE)–Cyrus Biotech today announced that its protease CYR212 has been selected as its clinical candidate for chronic IgG-driven autoimmune diseases.